Medivation, Inc. (MDVN) on Thursday announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet.
Results showed that patients with mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease.
The benefit on the primary endpoint, the Alzheimer's Disease Assessment Scale-cognitive subscale at six months, was highly significant. Patients treated with Dimebon were also significantly improved at six months over baseline on all measures. Dimebon's benefit over placebo continued to increase throughout the 12-month treatment period.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.